Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2023

Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma

C. Ottensmeier, et al. ASCO 2023  Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation

Published 26 May 2023
Categorized as 2023, Myvac, Publication, TG4050

Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

Published 26 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050

Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers

C. Le Tourneau, et al. ESMO 2023 Abstract available on the ESMO website – Download the abstract – Download the poster

Published 25 May 2023
Categorized as 2023, Publication, TG4001, TG4001

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001

Published 25 May 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Invir.IO, Press release

Transgene provides business update and Q1 2023 financial position

business update and Q1 2023 financial position 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer

First patient dosed in Phase I trial evaluating TG6050 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Press release, TG6050-en

Transgene’s Combined General Meeting of May 5, 2023

Transgene’s combined general meeting 15

Published 5 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio 15

Published 5 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

H. Le et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

P Erbs et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu